10 June 2016
06 June 2016
IntegraGen presented positive clinical results on its miR-31-3p biomarker during the 2016 American Society of Clinical Oncology (ASCO) Annual Meeting being held in Chicago. The data presented demonstrates that IntegraGen’s proprietary miR-31-3p biomarker is predictive for both survival and treatment response in patients receiving anti-EGFR therapy.
19 May 2016
Results of study focusing on miR-31-3p expression in patients enrolled in FIRE-3 trial to be presented during ASCO 2016
The results from an analysis of miR 31-3p expression for metastatic colorectal cancer (mCRC) patients enrolled in the FIRE-3 trial will be presented at ASCO 2016 in Chicago during a poster discussion session being held from 1:15 p.m. to 2:30 p.m. on Saturday, June 4, 2016 (Hall D). (…) »
16 February 2016
IntegraGen’s oncology Scientific Advisory Board (SAB) recently met at the venue of the 2016 American Society of Oncology’s (ASCO) Gastrointestinal Cancers Symposium in San Francisco to review the results from the latest clinical study exploring the predictivity of miR-31-3p on the efficacy of anti-EGFR therapy in all-RAS wild-type metastatic colorectal cancer (…) »
02 December 2015
IntegraGen Collaborating with FIRE-3 Clinical Trial Investigators to Study hsa-miR-31-3p Metastatic Colorectal Cancer Biomarker
IntegraGen announced a collaboration with investigators from the FIRE-3 clinical trial (AIO KRK-0306) to further study the oncology biomarker hsa-miR-31-3p, a microRNA whose expression has been shown to be associated with anti-EGFR effect in patients with metastatic colorectal cancer (mCRC) treated with anti-EGFR therapy.
01 June 2015
Results from two new studies exploring the role of the microRNA biomarker miR-31-3p in patients with metastatic colorectal cancer were presented during the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting. The studies reported positive results on the association between miR-31-3p expression and clinical outcomes in metastatic colorectal cancer (mCRC) patients treated with (…) »
22 April 2015
Data from two studies reporting results from clinical studies with IntegraGen’s miR-31-3p biomarker is scheduled to be presented during the 51st Annual Meeting of the American Society of Clinical Oncology (ASCO) being held in Chicago on May 29 through June 2, 2015.
The first study will report results from research conducted in cooperation (…) »
16 April 2015
Results from a study exploring the role of the microRNA biomarker miR-31-3p in patients with advanced adenocarinoma of the lung were presented during the 2015 European Lung Cancer Conference (ELCC) held in Geneva, Switzerland. The data presented demonstrated that the expression of miR-31-3p is associated with the histological type of the (…) »
16 December 2014
IntegraGen has announced a collaboration with the team of investigators from the PICCOLO study to further validate the role of biomarker hsa-miR-31-3p in metastatic colorectal cancer (mCRC).
15 December 2014
IntegraGen has announced that it has entered into an agreement providing the company with the worldwide licensing rights for two hepatocellular carcinoma molecular signatures which have potential clinical utility for monitoring patients with liver cancer.